253 related articles for article (PubMed ID: 20145158)
1. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.
Zoubeidi A; Chi K; Gleave M
Clin Cancer Res; 2010 Feb; 16(4):1088-93. PubMed ID: 20145158
[TBL] [Abstract][Full Text] [Related]
2. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
[TBL] [Abstract][Full Text] [Related]
3. Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells.
Zoubeidi A; Ettinger S; Beraldi E; Hadaschik B; Zardan A; Klomp LW; Nelson CC; Rennie PS; Gleave ME
Mol Cancer Res; 2010 Jan; 8(1):119-30. PubMed ID: 20068069
[TBL] [Abstract][Full Text] [Related]
4. Clusterin and chemoresistance.
Djeu JY; Wei S
Adv Cancer Res; 2009; 105():77-92. PubMed ID: 19879424
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin.
Muramaki M; So A; Hayashi N; Sowery R; Miyake H; Fujisawa M; Gleave ME
BJU Int; 2009 Feb; 103(3):384-90. PubMed ID: 19007378
[TBL] [Abstract][Full Text] [Related]
6. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.
Zielinski R; Chi KN
Future Oncol; 2012 Oct; 8(10):1239-51. PubMed ID: 23130925
[TBL] [Abstract][Full Text] [Related]
7. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer.
Chi KN; Zoubeidi A; Gleave ME
Expert Opin Investig Drugs; 2008 Dec; 17(12):1955-62. PubMed ID: 19012510
[TBL] [Abstract][Full Text] [Related]
8. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.
Zhong B; Sallman DA; Gilvary DL; Pernazza D; Sahakian E; Fritz D; Cheng JQ; Trougakos I; Wei S; Djeu JY
Mol Cancer Ther; 2010 Jun; 9(6):1831-41. PubMed ID: 20501799
[TBL] [Abstract][Full Text] [Related]
9. Potential use of custirsen to treat prostate cancer.
Higano CS
Onco Targets Ther; 2013; 6():785-97. PubMed ID: 23836992
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Saad F; Hotte S; North S; Eigl B; Chi K; Czaykowski P; Wood L; Pollak M; Berry S; Lattouf JB; Mukherjee SD; Gleave M; Winquist E;
Clin Cancer Res; 2011 Sep; 17(17):5765-73. PubMed ID: 21788353
[TBL] [Abstract][Full Text] [Related]
11. Small heat shock proteins in cancer therapy and prognosis.
Zoubeidi A; Gleave M
Int J Biochem Cell Biol; 2012 Oct; 44(10):1646-56. PubMed ID: 22571949
[TBL] [Abstract][Full Text] [Related]
12. Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen.
Blumenstein B; Saad F; Hotte S; Chi KN; Eigl B; Gleave M; Jacobs C
Cancer Med; 2013 Aug; 2(4):468-77. PubMed ID: 24156019
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of secretory clusterin (sCLU) induces chemotherapy resistance in human gastric cancer cells by targeting miR-195-5p.
Mu L; Yang F; Guo D; Li P; Zhang M
Bioengineered; 2020 Dec; 11(1):472-483. PubMed ID: 32250192
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.
Chi KN; Siu LL; Hirte H; Hotte SJ; Knox J; Kollmansberger C; Gleave M; Guns E; Powers J; Walsh W; Tu D; Eisenhauer E
Clin Cancer Res; 2008 Feb; 14(3):833-9. PubMed ID: 18245546
[TBL] [Abstract][Full Text] [Related]
15. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
Chi KN; Eisenhauer E; Fazli L; Jones EC; Goldenberg SL; Powers J; Tu D; Gleave ME
J Natl Cancer Inst; 2005 Sep; 97(17):1287-96. PubMed ID: 16145049
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.
So A; Sinnemann S; Huntsman D; Fazli L; Gleave M
Mol Cancer Ther; 2005 Dec; 4(12):1837-49. PubMed ID: 16373699
[TBL] [Abstract][Full Text] [Related]
17. Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression.
Wang Y; Wang X; Zhao H; Liang B; Du Q
J Chemother; 2012 Dec; 24(6):348-57. PubMed ID: 23174100
[TBL] [Abstract][Full Text] [Related]
18. Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer.
Niu ZH; Wang Y; Chun B; Li CX; Wu L
Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1337-44. PubMed ID: 23740447
[TBL] [Abstract][Full Text] [Related]
19. IGF-1 activates the P13K/AKT signaling pathway via upregulation of secretory clusterin.
Ma X; Bai Y
Mol Med Rep; 2012 Dec; 6(6):1433-7. PubMed ID: 23027041
[TBL] [Abstract][Full Text] [Related]
20. The chaperone activity of clusterin is dependent on glycosylation and redox environment.
Rohne P; Prochnow H; Wolf S; Renner B; Koch-Brandt C
Cell Physiol Biochem; 2014; 34(5):1626-39. PubMed ID: 25402950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
